



Lyon May 12th, 2025

Edelris is pleased to announce that they have entered into an agreement for the discovery of novel antimicrobial compounds with Santero Therapeutics

Following the successful results of an initial pilot study, Edelris and Santero Therapeutics have entered into an agreement to identify small-molecule antimicrobials using EDEN, the Edelris Discovery Engine. EDEN builds upon 20 years of research at Edelris into the design and synthesis of innovative compound libraries addressing an untapped yet relevant and highly tractable chemical space (the Keymical Collection™), coupled with cutting-edge high-throughput Affinity Selection Mass Spectrometry (AS-MS). This powerful combination enables the rapid identification of patentable chemical matter, even on difficult-to-drug targets, resulting in drug candidates with improved target specificity and favourable physicochemical properties. Under the agreement, Edelris will provide Santero with additional expert medicinal chemistry support for hit expansion to further optimize drug-like properties and will be eligible for additional payments upon a successful program. Further financial terms were not disclosed.

“Edelris is very proud to support the groundbreaking work of companies like Santero Therapeutics, who are addressing the critically important issue of antibiotic resistance. By leveraging our diverse Keymical Collection™ library of compounds, cutting-edge AS-MS technology, and decades of Medicinal Chemistry experience, we are committed to not only successfully identify hit compounds, but also to deliver molecules with ideal drug-like properties in order to help tackle this challenging area of research,” said Joseph Zolnerciks, Ph.D., Chief Business Officer of Edelris.

“Santero is looking forward to work with Edelris to identify novel antimicrobial compounds with a novel mode of action. The innovative chemistry developed by Edelris combined with their advanced screening technologies makes for an exciting partnership in this challenging endeavour. We anticipate that novel chemical architectures will be the key to develop efficient and safe first-in-class antimicrobials and Edelris technology is offering a promising route to meet such goal,” said Prof Cedric Govaerts, Ph.D., Managing Director of Santero.